2
|
Hatzipantelis C, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ. Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacol Transl Sci 2020; 3:1042-1062. [PMID: 33344888 PMCID: PMC7737210 DOI: 10.1021/acsptsci.0c00117] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Indexed: 01/07/2023]
Abstract
There are no effective therapeutics for cognitive impairments associated with schizophrenia (CIAS), which includes deficits in executive functions (working memory and cognitive flexibility) and episodic memory. Compounds that have entered clinical trials are inadequate in terms of efficacy and/or tolerability, highlighting a clear translational bottleneck and a need for a cohesive preclinical drug development strategy. In this review we propose hippocampal-prefrontal-cortical (HPC-PFC) circuitry underlying CIAS-relevant cognitive processes across mammalian species as a target source to guide the translation-focused discovery and development of novel, procognitive agents. We highlight several G protein-coupled receptors (GPCRs) enriched within HPC-PFC circuitry as therapeutic targets of interest, including noncanonical approaches (biased agonism and allosteric modulation) to conventional clinical targets, such as dopamine and muscarinic acetylcholine receptors, along with prospective novel targets, including the orphan receptors GPR52 and GPR139. We also describe the translational limitations of popular preclinical cognition tests and suggest touchscreen-based assays that probe cognitive functions reliant on HPC-PFC circuitry and reflect tests used in the clinic, as tests of greater translational relevance. Combining pharmacological and behavioral testing strategies based in HPC-PFC circuit function creates a cohesive, translation-focused approach to preclinical drug development that may improve the translational bottleneck currently hindering the development of treatments for CIAS.
Collapse
Affiliation(s)
- Cassandra
J. Hatzipantelis
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Monica Langiu
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Teresa H. Vandekolk
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Tracie L. Pierce
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Jess Nithianantharajah
- Florey
Institute of Neuroscience
and Mental Health, University of Melbourne, Parkville, Victoria 3052, Australia
| | - Gregory D. Stewart
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Christopher J. Langmead
- Drug
Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| |
Collapse
|
3
|
Haynes JM, Selby JN, Vandekolk TH, Abad IPL, Ho JK, Lieuw WL, Leach K, Savige J, Saini S, Fisher CL, Ricardo SD. Induced Pluripotent Stem Cell-Derived Podocyte-Like Cells as Models for Assessing Mechanisms Underlying Heritable Disease Phenotype: Initial Studies Using Two Alport Syndrome Patient Lines Indicate Impaired Potassium Channel Activity. J Pharmacol Exp Ther 2018; 367:335-347. [PMID: 30104322 DOI: 10.1124/jpet.118.250142] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Accepted: 07/26/2018] [Indexed: 12/22/2022] Open
Abstract
Renal podocyte survival depends upon the dynamic regulation of a complex cell architecture that links the glomerular basement membrane to integrins, ion channels, and receptors. Alport syndrome is a heritable chronic kidney disease where mutations in α3, α4, or α5 collagen genes promote podocyte death. In rodent models of renal failure, activation of the calcium-sensing receptor (CaSR) can protect podocytes from stress-related death. In this study, we assessed CaSR function in podocyte-like cells derived from induced-pluripotent stem cells from two patients with Alport Syndrome (AS1 & AS2) and a renal disease free individual [normal human mesangial cell (NHMC)], as well as a human immortalized podocyte-like (HIP) cell line. Extracellular calcium elicited concentration-dependent elevations of intracellular calcium in all podocyte-like cells. NHMC and HIP, but not AS1 or AS2 podocyte-like cells, also showed acute reductions in intracellular calcium prior to elevation. In NHMC podocyte-like cells this acute reduction was blocked by the large-conductance potassium channel (KCNMA1) inhibitors iberiotoxin (10 nM) and tetraethylammonium (5 mM), as well as the focal adhesion kinase inhibitor PF562271 (N-methyl-N-(3-((2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl)-pyridin-2-yl)-methanesulfonamide, 10 nM). Quantitative polymerase chain reaction (qPCR) and immunolabeling showed the presence of KCNMA1 transcript and protein in all podocyte-like cells tested. Cultivation of AS1 podocytes on decellularized plates of NHMC podocyte-like cells partially restored acute reductions in intracellular calcium in response to extracellular calcium. We conclude that the AS patient-derived podocyte-like cells used in this study showed dysfunctional integrin signaling and potassium channel function, which may contribute to podocyte death seen in Alport syndrome.
Collapse
Affiliation(s)
- John M Haynes
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - James N Selby
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Teresa H Vandekolk
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Isaiah P L Abad
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Joan K Ho
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Wai-Ling Lieuw
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Katie Leach
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Judith Savige
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Sheetal Saini
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Craig L Fisher
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| | - Sharon D Ricardo
- Monash Institute of Pharmaceutical Sciences (J.M.H., J.N.S., T.H.V., I.P.L.A., J.K.H., W.-L.L., K.L.) and Department of Anatomy and Developmental Biology (S.S., C.L.F., S.D.R.), Monash University, Victoria, Australia; and Department of Medicine, Royal Melbourne Hospital, Victoria, Australia (J.S.)
| |
Collapse
|